IP Library Granted Patent US 7,683,158
Granted Patent B2
US 7,683,158 · App. 11/729,625 · Granted Mar 23, 2010

Pegylated factor VIII

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,683,158
App. No.
11/729,625
Granted
Mar 23, 2010
Kind
B2
Abstract

The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.

Claims (9)

1. A proteinaceous molecule comprising, (a) a Factor VIII molecule having the B domain intact; and (b) at least four polyethylene glycol molecules bound to said Factor VIII molecule, wherein three polyethylene glycol molecules are bound to said Factor VIII molecule in the A3 domain and at least one polyethylene glycol molecule is bound to said Factor VIII molecule in the B domain; said polyethylene glycol molecules having a molecular weight of about 15,000 Daltons to about 150,000 Daltons; said proteinaceous molecule having a biological activity of at least 80% of the biological activity of native Factor VIII, wherein the biological activities of the proteinaceous molecule and of native Factor VIII are determined by the ratios of chromogenic activity to Factor VIII antigen value (FVIII:Chr/FVIII:Ag), and wherein the in vivo half-life of said proteinaceous molecule is increased by at least 1.5-fold as compared to the in vivo half-life of native Factor VIII.

2. The proteinaceous molecule of claim 1 wherein said proteinaceous molecule has a biological activity of at least 90% of the biological activity of native Factor VIII.

3. The proteinaceous molecule of claim 1 wherein said Factor VIII molecule is a recombinant Factor VIII.

4. The proteinaceous molecule of claim 1 wherein said Factor VIII molecule is full-length Factor VIII.

5. The proteinaceous molecule of claim 1 wherein said polyethylene glycol molecules have a molecular weight of about 15,000 to about 20,000 Da.

6. The proteinaceous molecule of claim 1 wherein said polyethylene glycol molecules have a molecular weight of about 18,000 to about 25,000 Da.

7. The proteinaceous molecule of claim 1 wherein said polyethylene glycol molecules have a molecular weight of about 20,000 Da.

8. The proteinaceous molecule of claim 1 wherein said polyethylene glycol molecules have a molecular weight of about 20,000 to about 150,000 Da.

9. The proteinaceous molecule of claim 1 wherein said polyethylene glycol molecules have a linear or branched structure.

Assignments (6)
SECURITY INTEREST Recorded May 6, 2025
From: ALIANZA, INC.; METASWITCH NETWORKS LTD
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 071191/0228 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036359 FRAME: 0631. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 24, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036433/0699 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036359/0631 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036373/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2007
From: SIEKMANN, JUERGEN; VARADI, KATALIN; GRITSCH, HERBERT; TURECEK, PETER
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 019513/0922 →